NCT01205230View on ClinicalTrials.gov

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Cancer
Interventions
DRUG

pazopanib

Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)

Trial Locations (2)

29605

GSK Investigational Site, Greenville

08901

GSK Investigational Site, New Brunswick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY